t(10;11)(q25;p15)

Review on t(10;11)(q25;p15), with data on clinics, and the genes involved

PDGFRB (platelet-derived growth factor receptor, beta polypeptide)

Review on PDGFRB (platelet-derived growth factor receptor, beta polypeptide), with data on DNA, on the protein encoded, and where the gene is implicated

ADD3 (adducin 3)

Review on ADD3 (adducin 3), with data on DNA, on the protein encoded, and where the gene is implicated

Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients

BACKGROUND: Rubinstein-Taybi Syndrome (RSTS, MIM 180849) is a rare congenital disorder characterized by mental and growth retardation, broad and duplicated distal phalanges of thumbs and halluces, facial dysmorphisms and increased risk of tumors. RSTS is caused by chromosomal rearrangements and point mutations in one copy of the CREB-binding protein gene (CREBBP or CBP) in 16p13.3. To date mutations in CREBBP have been reported in 56.6% of RSTS patients and an average figure of 10% has ascribed to deletions. METHODS: Our study is based on the mutation analysis of CREBBP in 31 Italian RSTS patients using segregation analysis of intragenic microsatellites, BAC FISH and direct sequencing of PCR and RT-PCR fragments. RESULTS: We identified a total of five deletions, two of the entire gene and three, all in a mosaic condition, involving either the 5' or the 3' region. By direct sequencing a total of 14 de novo mutations were identified: 10 truncating (5 frameshift and 5 nonsense), one splice site, and three novel missense mutations. Two of the latter affect the HAT domain, while one maps within the conserved nuclear receptor binding of (aa 1–170) and will probably destroy a Nuclear Localization Signal. Identification of the p.Asn1978Ser in the healthy mother of a patient also carrying a de novo frameshift mutation, questions the pathogenetic significance of the missense change reported as recurrent mutation. Thirteen additional polymorphisms, three as of yet unreported, were also detected. CONCLUSION: A high detection rate (61.3%) of mutations is confirmed by this Italian study which also attests one of the highest microdeletion rate (16%) documented so far

t(10;16)(q22;p13)

Review on t(10;16)(q22;p13), with data on clinics, and the genes involved

t(5;14)(q33;q24)

Review on t(5;14)(q33;q24), with data on clinics, and the genes involved

NIN (ninein (GSK3B interacting protein))

Review on NIN (ninein (GSK3B interacting protein)), with data on DNA, on the protein encoded, and where the gene is implicated

MYST4 (MYST histone acetyltransferase (monocytic leukemia) 4)

Review on MYST4 (MYST histone acetyltransferase (monocytic leukemia) 4), with data on DNA, on the protein encoded, and where the gene is implicated

8p11 myeloproliferative syndrome (EMS, eight p11 myeloproliferative syndrome)

Review on 8p11 myeloproliferative syndrome (EMS, eight p11 myeloproliferative syndrome), with data on clinics, and the genes involved